Rehabilitation of patellar tendinopathy Musculoskeletal Diseases
Conditions
Interventions
Current interventions as of 17/02/2025:
The sample will consist of two groups of individuals with patellar tendinopathy which will be randomly assigned (in a 1:1 allocation ratio to parallel groups us
or eccentric exercise [EE] group (n = 16), with one control group consisting of healthy controls (n = 26), which will just be assessed at baseline.
A baseline assessment will be taken for all partici
pennation angle and length), morphological (thickness) and tendon morphomechanical (thickness, cross-sectional area, and stiffness) properties will be conducted.
Post-baseline assessments, the TF and
Sponsors
University of Birmingham
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 17/02/2025: Tendinopathy group 1. 18 to 55 years old 2. Male or female 3. History of patellar tendinopathy for at least 3 months. Signs of patellar tendinopathy on ultrasound imaging (i.e., increased tendon thickness and cross-sectional area). 4. Current pain (pain of at least 2/10 on a numeric rating scale, when performing a single leg eccentric squat) located only at the patellar tendon during movement activities such as jumping and squatting, verified by using a single leg eccentric squat test, with the presence of a pain level of at least 2/10 on a VAS scale. 5. Score of less or equal to 80 on the Victorian Institute of Sport Assessment Scale-Patella (VISA-P). 6. Not receiving any NHS treatment for patellar tendinopathy in the preceding three months from the start of the study. Healthy control group 1. Healthy physically active males and females aged between 18 and 55 years old. 2. Not have had any knee pain in the last 12 months. 3. No history of patellar tendinopathy Previous inclusion criteria: Tendinopathy group 1. 18 to 55 years old 2. Male or female 3. History of patellar tendinopathy for at least 3 months. Signs of patellar tendinopathy on ultrasound imaging (i.e., increased tendon thickness and cross-sectional area). 4. Current pain should be located only in the patellar tendon and experienced during physical activities such as jumping and squatting. 5. Score of less or equal to 80 on the Victorian Institute of Sport Assessment Scale-Patella (VISA-P). 6. Not receiving any NHS treatment for patellar tendinopathy. Healthy control group 1. Healthy physically active males and females aged between 18 and 55 years old. 2. Not have had any knee pain in the last 12 months. 3. No history of patellar tendinopathy
Exclusion criteria
Exclusion criteria: 1. Systemic or inflammatory conditions including rheumatic and neuromuscular disorders 2. Previously had lower-limb surgery without full rehabilitation 3. Known presence of inflammatory joint diseases 4. Familial hypercholesterolaemia 5. Daily use of drugs with a putative effect on the patellar tendon in the preceding 12 months (eg, fluoroquinolones) 6. Local injection therapy with corticosteroids in the preceding 12 months 7. Previous patellar tendon rupture 8. Inability to perform an exercise programme 9. participation in other concomitant treatment programmes 10. Signs or symptoms of other coexisting knee pathology on physical examination or ultrasound/MRI 11. Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measure as of 17/02/2025: At baseline, 3, 6, 12 and 18 weeks: 1. Pain assessed by a numerical rating scale (NRS) 2. Perceived functional disability measured by the Victorian Institute of Sport Assessment - patella (VISA-P) questionnaire Previous primary outcome measure: At baseline, 3, 6, 12 and 24 weeks: 1. Pain assessed by a numerical rating scale (NRS) 2. Perceived functional disability measured by the Victorian Institute of Sport Assessment - patella (VISA-P) questionnaire | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 17/02/2025: At baseline, 3 and 6 weeks: 1. Level of physical activity monitored with the IPAQ-SF scale 2. Level of Kinesiophobia measured with the Tampa scale for kinesiophobia (TSK) 3. Maximal knee extension strength - Peak knee extension torque (Nm) 4. Torque tracking accuracy - Coefficient of variation of torque (%) 5. Motor unit firing properties - Mean motor unit discharge rate (pps), discharge rate variability (%) and recruitment threshold (% MVT). 6. Quadriceps muscle connectivity/synchronization - Motor unit intermuscular coherence (Hz) 7. Thigh (Quadriceps) muscle thickness (mm), pennation angle (°), length (mm) measured with ultrasound imaging by placing the probe perpendicular to the skin above the three quadricep muscles (vastus lateralis, rectus femoris, vastus medialis). 8. Tendon thickness (mm) measured with ultrasound imaging, by placing the probe perpendicular to the skin directly above the tibial tuberosity in the sagittal (longitudinal) plane. A linear measurement (mm) will be taken at the proximal, middle, and distal portions of the tendon between the paratenon and epitenon. 9. Tendon stiffness (Kpa) and shear wave velocity (m/s), estimated via shearwave elastography Previous secondary outcome measures: At baseline, 3 and 6 weeks: 1. Level of physical activity monitored with the IPAQ scale 2. Level of Kinesiophobia measured with the Tampa scale for kinesiophobia (TSK) 3. Maximal knee extension strength - Peak knee extension torque (Nm) 4. Torque tracking accuracy - Coefficient of variation of torque (%) 5. Motor unit firing properties - Mean motor unit discharge rate (pps), discharge rate variability (%) and recruitment threshold (% MVT). 6. Quadriceps muscle connectivity/synchronization - Motor unit intermuscular coherence (Hz) 7. Tendon thickness (mm) measured with ultrasound imaging, by placing the probe perpendicular to the skin directly above the tibial tuberosity in the sagittal (longitudinal) pla | — |
Countries
England, United Kingdom
Contacts
Public ContactEduardo Martinez-Valdes
Outcome results
None listed